Abstract 5107
Background
Brain metastases are currently both common in clinical oncology and a critical problem, since they negatively affect patients' quality of life as well as survival. In the era of targeted therapy, survival for metastatic, recurrent lung cancer has improved. However, improved systemic treatment modalities have led to prolonged disease courses and subsequently to an increased incidence of brain metastases.
Methods
We recruited patients who were diagnosed with non-small cell lung cancer at a Samsung Medical Center from 2008 to 2017. We collected clinical characteristics and treatment pattern by medical chart review and analyzed their mutation status by NGS (ampliseq and cancer scan).
Results
Among 12918 patients who were diagnosed with non-small cell lung cancer and received chemotherapy, 1566 patients received gamma knife surgery and 1209 patients received whole brain radiotherapy. 3922 were EGFR mutant non-small cell lung cancers and received EGFR tyrosine kinase inhibitors (erlotinib: 1424; gefitinib: 2210; afatinib: 606; dacomitinib: 24). Among EGFR-mutant patients, 663 (16.9%) patients received whole brain radiation therap (WBRT) and 765 (19.5%) received gamma-knife surgery. 320 patients who were diagnosed with ALK-positive non-small cell lung cancer received ALK inhibitors (crizotinib: 308; alectinib 54). Among them 51 (15.9%) received WBRT and 81 (25.3%) patients received gamma-knife surgery. 268 patients received gamma-knife surgery three times or more. 51 patients received gamma-knife surgery five times or more (maximum 14 of gamma-knife surgery). Among them, 27 (52.9%) patients were EGFR mutant and 11 (21.6%) patients were ALK-rearrangement non-small cell lung cancer.
Conclusions
In patients with EGFR-mutant or ALK-rearrangement non-small cell lung cancer, local treatment for brain metastasis was performed frequently. A minority of patients have well controlled extracranial disease but poorly controlled intracranial disease, and in these cases strategies to maintain systemic chemotherapy and persistent topical treatments for brain lesions are also helpful. Further research is needed to find out the unique tumor biology of patients with uncontrolled brain metastases.
Clinical trial identification
Legal entity responsible for the study
SMC IRB.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2300 - AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)
Presenter: Claudia Cardone
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2834 - Multimodal detection of homologous recombination repair gene mutations (HRRm) in a Phase II trial of olaparib plus abiraterone in metastatic castrate resistant prostate cancer (mCRPC)
Presenter: Thomas Carr
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3596 - Identification of a highly suppressive Treg subset associated to immunotherapy response
Presenter: Emilio Giunta
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3705 - A Novel Framework for Evaluating Biomarker Response Relationships in Immuno-oncology (IO)
Presenter: Jeffrey Evelhoch
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5332 - Comparison of OncoBEAM and NGS methods to detect plasma EGFR T790M mutations at progression of NSCLC
Presenter: Jessica Garcia
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5700 - Differential expression of PD-L1 and immune biomarkers by age: Decreased expression in pediatric/AYA patients with advanced cancer
Presenter: Omid Hamid
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
966 - Potential resistance mechanisms revealed primary resistance to crizotinib in ROS1+ non-small-cell lung cancer using next generation sequencing: A multicenter study
Presenter: Quxia Zhang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2171 - Prevalence of CLDN18.2, HER2, and PD-L1 in Gastric Cancer Samples
Presenter: Diarmuid Moran
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2318 - Epigenetic markers in circulating cell-free DNA for detection of early stage colorectal cancer
Presenter: Yanqun Liu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3625 - Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292
Presenter: Benjamin Besse
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract